Rethinking clinical oncology drug research in an era of value‐based cancer care: A role for chemotherapy pathways

The United States spends nearly 1/5th of its GDP on healthcare. Yet, to achieve value‐based care, the Economist describes the US healthcare system as handicapped by multiple, disparate silos that prevent the organization and sharing of data. This paper explores the current state of clinical oncology...

Full description

Saved in:
Bibliographic Details
Published inCancer medicine (Malden, MA) Vol. 9; no. 15; pp. 5306 - 5311
Main Author Hoverman, J. Russell
Format Journal Article
LanguageEnglish
Published United States John Wiley & Sons, Inc 01.08.2020
John Wiley and Sons Inc
Wiley
Subjects
cancer management
Cancer therapies
Chemotherapy
Clinical Cancer Research
Clinical trials
Costs
Drug dosages
Guanosine diphosphate
Marketing
medical oncology
Medical research
Oncology
Review
Studies
Tumors
United States > US
medical oncology
chemotherapy
clinical cancer research
cancer management
Online AccessGet full text

Cover

More Information
Summary:The United States spends nearly 1/5th of its GDP on healthcare. Yet, to achieve value‐based care, the Economist describes the US healthcare system as handicapped by multiple, disparate silos that prevent the organization and sharing of data. This paper explores the current state of clinical oncology drug research and its relationship to value‐based cancer care. Clinical Chemotherapy Pathways are proposed as a unifying structure to bring together disparate sources of data to increase value. There are many inconsistencies to cancer drug research that make it challenging to assign value. The systematic use of clinical pathways can enable the efficient use of novel therapies.
Bibliography:Funding information
No external funding was involved in preparation of this manuscript.
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:2045-7634
2045-7634
DOI:10.1002/cam4.3193